Vir Biotechnology (VIR) PT Raised to $61 at Goldman Sachs, Following Earnings
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs analyst Paul Choi raised the price target on Vir Biotechnology (NASDAQ: VIR) to $61.00 (from $54.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) and Vir Biotechnology (VIR) Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
- flatexDEGIRO AG (FTKn:GR) (FNNTF) PT Raised to EUR120 at Goldman Sachs
- Hana Financial Group (086790:KS) PT Raised to KRW51,000 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesGoldman Sachs, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!